#1 Clinical Trials Search in Europe

Retroviral Vector Containing The Common Gamma Chain Cdna

This article discusses an innovative clinical trial investigating the use of MC2 TCR T cell therapy, combined with epigenetic drug treatment, for patients with advanced melanoma or head and neck squamous cell carcinoma (HNSCC). The study aims to evaluate the safety, feasibility, and efficacy of this novel approach in treating these challenging cancers.

Table of Contents

What is MAGE-C2 TCR T Cell Therapy?

MAGE-C2 TCR T Cell Therapy is an innovative treatment being studied for patients with advanced melanoma and head and neck cancer. This therapy uses a special type of immune cells called T cells, which are modified to target a specific protein called MAGE-C2 found on some cancer cells[1].

The treatment involves using a retroviral vector (a modified virus that can’t cause disease) to introduce genetic material into the patient’s own T cells. This genetic material contains instructions for producing a special receptor called a T cell receptor (TCR) that can recognize the MAGE-C2 protein[1].

How Does It Work?

The therapy works in several steps:

  1. Doctors collect T cells from the patient’s blood.
  2. In a laboratory, these T cells are modified using a retroviral vector to produce the special TCR that recognizes MAGE-C2.
  3. The modified T cells, now called MC2 TCR T cells, are grown in large numbers.
  4. The patient receives a treatment to prepare their body for the therapy.
  5. The MC2 TCR T cells are then infused back into the patient’s body.
  6. These modified T cells can now recognize and attack cancer cells that have the MAGE-C2 protein on their surface[1].

This treatment is combined with epigenetic drug treatment, which may help make the therapy more effective by changing how genes are expressed in cancer cells[1].

Target Conditions

This therapy is being studied for patients with:

  • Advanced melanoma: A serious type of skin cancer that has spread or can’t be removed by surgery. This includes melanoma of the eye (ocular) and mucous membranes (mucosal).
  • Head and neck squamous cell carcinoma (HNSCC): A type of cancer that starts in the cells lining the mouth, nose, and throat[1].

The therapy is intended for patients whose cancer has progressed after standard treatments or has come back after previous treatment[1].

Clinical Trial Details

The treatment is currently being studied in a clinical trial that has two parts:

  • Phase I: This part of the study focuses on finding the safe dose of MC2 TCR T cells and checking if the treatment is feasible.
  • Phase II: This part looks at how well the treatment works at the dose determined in Phase I[1].

The trial is looking at several important factors, including:

  • How safe the treatment is and what side effects it might cause
  • How well the modified T cells survive and function in the body
  • How the patient’s immune system responds to the treatment
  • Whether the treatment causes tumors to shrink or disappear[1]

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Some key requirements include:

  • Being 18 years of age or older
  • Having advanced melanoma or head and neck cancer that has progressed after standard treatments
  • Being HLA-A2 positive (a specific genetic marker)
  • Having a tumor that is positive for the MAGE-C2 protein
  • Being in relatively good overall health (ECOG performance status of 0 or 1)[1]

There are also some conditions that would prevent a person from participating, such as having active brain metastases or needing steroid therapy[1].

Potential Benefits and Outcomes

The main goals of this treatment are to:

  • Shrink or eliminate tumors
  • Prevent the cancer from progressing
  • Extend the time patients live without their cancer getting worse
  • Improve overall survival[1]

The study will measure these outcomes to determine how effective the treatment is. It’s important to note that as this is an experimental therapy, its effectiveness is still being evaluated[1].

Safety Considerations

As with any new treatment, safety is a top priority. The study will carefully monitor patients for any side effects or adverse events. Some potential risks could include:

  • Reactions to the cell infusion
  • Changes in the immune system
  • Side effects from the epigenetic drugs used in combination with the T cell therapy[1]

Patients in the study will be closely monitored and any side effects will be managed by the medical team[1].

Aspect Details
Study Type Phase I/II clinical trial
Target Conditions Advanced melanoma and head and neck squamous cell carcinoma (HNSCC)
Treatment MC2 TCR T cell therapy combined with epigenetic drug treatment
Main Objectives Assess safety, determine maximum tolerated dose, evaluate efficacy
Key Eligibility Criteria 18+ years, HLA-A2 positive, MAGE-C2 positive tumors
Primary Endpoints Adverse events, recommended Phase II dose, objective response rate
Secondary Endpoints T cell persistence, cytokine release, immune parameters, progression-free survival

FAQ

  • What is MC2 TCR T cell therapy? MC2 TCR T cell therapy is a type of adoptive cell therapy that uses genetically engineered T cells to target a specific protein called MAGE-C2, which is found in some melanoma and head and neck cancer cells.
  • Who is eligible for this clinical trial? Eligible participants must be 18 years or older, have inoperable stage IIIc or stage IV melanoma or recurrent/metastatic HNSCC, be HLA-A2 positive, have MAGE-C2 positive tumors, and meet other specific criteria outlined in the study protocol.
  • What are the main objectives of the trial? The main objectives are to assess the safety and feasibility of the treatment in Phase I, determine the maximum tolerated dose of MC2 TCR T cells, and evaluate the efficacy of the treatment in Phase II using tumor response criteria.
  • What does the treatment involve? The treatment involves administering autologous (patient's own) MC2 TCR T cells combined with epigenetic drug treatment. The T cells are engineered using a retroviral vector to target cancer cells expressing the MAGE-C2 protein.
  • How will the effectiveness of the treatment be measured? The effectiveness will be measured through various endpoints, including adverse events, objective response rate, progression-free survival, duration of response, and overall survival. The study will also monitor the persistence and function of MC2-specific T cells in the blood and analyze immune parameters in blood and tumor tissues.

Ongoing Clinical Trials on Retroviral Vector Containing The Common Gamma Chain Cdna

  • Study of MC2 TCR T Cell Therapy and Epigenetic Drug Treatment for Patients with Advanced Melanoma or Head and Neck Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Adoptive therapy: A type of cancer treatment that involves collecting and using the patient's own immune cells to treat their cancer.
  • TCR (T Cell Receptor): A molecule on the surface of T cells that recognizes specific targets on cancer cells.
  • MAGE-C2: A protein found in some melanoma and head and neck cancer cells that can be targeted by engineered T cells.
  • Epigenetic drug treatment: Medications that can modify gene expression without changing the DNA sequence, potentially making cancer cells more vulnerable to treatment.
  • HLA-A2: A specific type of human leukocyte antigen (HLA) that is important for the immune system's ability to recognize and respond to certain targets.
  • ECOG performance status: A scale used to assess a patient's level of functioning in terms of their ability to care for themselves and engage in daily activities.
  • CTCAE: Common Terminology Criteria for Adverse Events, a standardized system for reporting side effects in cancer clinical trials.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Retroviral vector: A tool used to deliver genetic material into cells, in this case, to engineer T cells to target specific cancer proteins.
  • Autologous: Derived from the patient's own cells or tissues.

References

  1. http://clinicaltrials.eu/trial/study-of-mc2-tcr-t-cell-therapy-and-epigenetic-drug-treatment-for-patients-with-advanced-melanoma-or-head-and-neck-cancer/